Finemedix Co., Ltd. (KOSDAQ:387570)
South Korea · Delayed Price · Currency is KRW 7,390.00
+90.00 (1.23%)
At close: Jan 29, 2026
Finemedix Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 10,484 | 9,960 | 10,154 | 8,142 | 7,254 | 7,910 |
Other Revenue | - | - | -0 | -0 | - | -0 |
| 10,484 | 9,960 | 10,154 | 8,142 | 7,254 | 7,910 | |
Revenue Growth (YoY) | 12.92% | -1.91% | 24.71% | 12.25% | -8.30% | 3.94% |
Cost of Revenue | 5,147 | 4,255 | 4,514 | 3,736 | 3,811 | 4,015 |
Gross Profit | 5,336 | 5,705 | 5,640 | 4,406 | 3,443 | 3,895 |
Selling, General & Admin | 5,843 | 4,761 | 3,904 | 4,023 | 4,417 | 2,900 |
Research & Development | 621.95 | 554.53 | 497.78 | 650.75 | 819.38 | 828.52 |
Amortization of Goodwill & Intangibles | 49.75 | 59.4 | 45.97 | 52.11 | 70.68 | 42.66 |
Other Operating Expenses | 164.77 | 149.61 | 135.96 | 149.65 | 164.85 | 125.93 |
Operating Expenses | 7,087 | 5,841 | 4,767 | 5,067 | 5,756 | 4,223 |
Operating Income | -1,751 | -135.69 | 873.58 | -661.25 | -2,313 | -327.83 |
Interest Expense | -92.8 | -116.61 | -198.81 | -255.4 | -239.15 | -281.43 |
Interest & Investment Income | 88.62 | 39.31 | 48.77 | 34.91 | 7.96 | 50.7 |
Earnings From Equity Investments | - | - | - | -200 | - | - |
Currency Exchange Gain (Loss) | 127.51 | 195.54 | -29.72 | 5.9 | 34.46 | -31.66 |
Other Non Operating Income (Expenses) | 9.37 | -8.41 | 483.89 | 27.5 | 305.59 | 23.8 |
EBT Excluding Unusual Items | -1,619 | -25.86 | 1,178 | -1,048 | -2,204 | -566.41 |
Gain (Loss) on Sale of Investments | - | - | - | - | -6.15 | -56.8 |
Gain (Loss) on Sale of Assets | -180 | -180 | - | 1,342 | 10.53 | 5.11 |
Other Unusual Items | - | - | - | - | - | -184.29 |
Pretax Income | -1,799 | -205.86 | 1,178 | 293.67 | -2,200 | -802.4 |
Income Tax Expense | -354.8 | -181.71 | 1.84 | 54.09 | -657.02 | 262 |
Earnings From Continuing Operations | -1,444 | -24.15 | 1,176 | 239.58 | -1,543 | -1,064 |
Minority Interest in Earnings | - | - | - | - | 133.47 | - |
Net Income | -1,444 | -24.15 | 1,176 | 239.58 | -1,410 | -1,064 |
Net Income to Common | -1,444 | -24.15 | 1,176 | 239.58 | -1,410 | -1,064 |
Net Income Growth | - | - | 390.80% | - | - | - |
Shares Outstanding (Basic) | 5 | 5 | 5 | 5 | 3 | 3 |
Shares Outstanding (Diluted) | 5 | 5 | 5 | 5 | 3 | 3 |
Shares Change (YoY) | 13.80% | 0.72% | 1.75% | 38.53% | 9.53% | -21.07% |
EPS (Basic) | -276.40 | -5.32 | 261.11 | 53.20 | -433.59 | -358.62 |
EPS (Diluted) | -276.40 | -5.32 | 257.00 | 53.00 | -434.00 | -359.00 |
EPS Growth | - | - | 384.91% | - | - | - |
Free Cash Flow | -3,534 | -424.77 | 1,042 | -2,127 | -875.99 | -5,477 |
Free Cash Flow Per Share | -676.53 | -92.03 | 227.36 | -472.25 | -269.47 | -1845.24 |
Gross Margin | 50.90% | 57.28% | 55.55% | 54.12% | 47.46% | 49.24% |
Operating Margin | -16.71% | -1.36% | 8.60% | -8.12% | -31.89% | -4.14% |
Profit Margin | -13.77% | -0.24% | 11.58% | 2.94% | -19.43% | -13.46% |
Free Cash Flow Margin | -33.71% | -4.26% | 10.26% | -26.12% | -12.08% | -69.24% |
EBITDA | -775.47 | 859.96 | 1,838 | 298.38 | -1,330 | 243.47 |
EBITDA Margin | -7.40% | 8.63% | 18.10% | 3.67% | -18.33% | 3.08% |
D&A For EBITDA | 975.85 | 995.65 | 964.01 | 959.62 | 983.4 | 571.29 |
EBIT | -1,751 | -135.69 | 873.58 | -661.25 | -2,313 | -327.83 |
EBIT Margin | -16.71% | -1.36% | 8.60% | -8.12% | -31.89% | -4.14% |
Effective Tax Rate | - | - | 0.16% | 18.42% | - | - |
Advertising Expenses | - | 114.74 | 189 | 153.45 | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.